肌层浸润性膀胱癌治疗对健康相关生活质量的影响
荷兰前瞻性队列研究纳入390例非转移性肌层浸润性膀胱癌患者,按治疗方案分组,在基线及6、12、24个月用EORTC QLQ-C30和QLQ-BLM30评估生活质量。结果显示总体生活质量在2年内基本恢复至基线,但RC(联合或不联合NAC)患者身体形象和性功能持续恶化,放疗患者呼吸困难进行性加重。
要点
- 所有治疗组在2年内情绪功能和未来展望均有临床相关改善
- RC(联合或不联合NAC)患者身体形象和性功能持续恶化至少2年
- 化疗放疗患者泌尿症状改善,单纯放疗患者呼吸困难显著加重
核心结论
- 肌层浸润性膀胱癌患者诊断后2年内健康相关生活质量总体恢复至基线水平。
- RC(联合或不联合NAC)患者身体形象和性功能持续恶化至少2年,泌尿造口相关结局改善。
研究设计与样本
- 前瞻性队列研究,纳入2017年11月至2019年11月荷兰诊断为非转移性(cM0)MIBC患者。
- 518例参与生活质量测量(应答率46%),排除14例未完成EORTC QLQ-C30及114例基线在治疗开始后完成者,最终纳入390例。
- 390例中105例接受NAC联合RC,148例接受 upfront RC,58例接受化疗放疗,79例接受单纯放疗。
- 使用EORTC QLQ-C30及MIBC特异性QLQ-BLM30模块,在基线(治疗前)及诊断后6、12、24个月发放问卷。
- 采用线性混合模型评估各治疗组生活质量随时间的变化。
主要发现
- 所有治疗组随时间推移在情绪功能和未来展望方面观察到临床相关改善。
- 6个月时观察到身体功能暂时性恶化。
- RC(联合或不联合NAC)患者身体形象和性功能持续恶化至少至诊断后2年,尽管泌尿造口相关结局改善。
- 化疗放疗患者泌尿症状改善。
- 单纯放疗患者呼吸困难随时间显著加重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of treatment for localised muscle-invasive bladder cancer (MIBC) during the first 2 years after diagnosis. PATIENTS AND METHODS: A prospective cohort study was conducted including patients diagnosed with non-metastatic (cM0) MIBC between November 2017 and November 2019 in the Netherlands. Health-related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) as well as the MIBC-specific QLQ-BLM30 module. Questionnaires were administered at baseline (pre-treatment) and at 6, 12 and 24 months after diagnosis. Patients were grouped by treatment: neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), upfront RC, chemoradiation, and radiotherapy. Linear mixed models were used to assess HRQoL changes over time per treatment group. RESULTS: A total of 518 patients participated in quality of life measurements (46% response rate). After excluding 14 patients who did not complete the EORTC QLQ-C30 and 114 for baseline completion after start of treatment, a total of 390 patients were included of whom 105 underwent NAC and RC, 148 underwent upfront RC, 58 underwent chemoradiation, and 79 underwent radiotherapy alone. Over time, clinically relevant improvements in emotional functioning and future perspective were observed across all treatment groups. However, a temporary worsening in physical functioning was observed at 6 months. Patients treated with RC (with or without NAC) experienced persistent deteriorations in body image and sexual functioning up to at least 2 years after diagnosis, although urostomy-related outcomes improved. Patients undergoing chemoradiation showed improvements in urinary symptoms, while those receiving radiotherapy reported significant worsening of dyspnoea over time. CONCLUSION: In this largest population-based study to date on HRQoL in MIBC, HRQoL largely recovered to baseline levels during the first 2 years after diagnosis. However, persistent deteriorations in physical and cognitive functioning, body image, and sexual function were observed, particularly in patients treated with RC (with or without NAC).
引用
- Nuijens ST, van Hoogstraten LMC, Terpstra NB, et al. The impact of treatment for muscle-invasive bladder cancer on health-related quality of life. BJU Int. 2025. PMID: 40241435. doi:10.1111/bju.16736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。